Feb 2025 $22 M Private placement after listing $10 to $50 million 12
OncoCyte Corp: Private sale, Feb 2025 × Investors in this round 12 investors had bought by the notice of Feb 24, 2025: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $22 M of $22 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Andrea James · Executive Officer · Chief Financial Officer James Liu · Executive Officer · Senior Director, Controller & Principal Accounting Officer Joshua Riggs · Executive Officer, Director · President and Chief Executive Officer and Director Andrew Arno · Director Andrew Last · Director Louis Silverman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “The Company did not engage a placement agent.”Signed by Joshua Riggs, President and Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Feb 24, 2025. Read the notice at the SEC .
equity, options SEC Oct 2024 $10 M Private placement after listing $10 to $50 million 16
OncoCyte Corp: Private sale, Oct 2024 × Investors in this round 16 investors had bought by the notice of Oct 8, 2024: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $250,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in California People named in the notice Andrea James · Executive Officer · Chief Financial Officer James Liu · Executive Officer · Senior Director, Controller & Principal Accounting Officer Joshua Riggs · Executive Officer, Director · President and Chief Executive Officer and Director Andrew Arno · Director Andrew Last · Director Louis Silverman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Needham & Company, LLC (CRD 000016360) · New York, New York Sold in NY Signed by Joshua Riggs, President and Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Oct 8, 2024. Read the notice at the SEC .
equity SEC Apr 2024 $16 M Private placement after listing $10 to $50 million 21
OncoCyte Corp: Private sale, Apr 2024 × Investors in this round 21 investors had bought by the notice of Apr 25, 2024: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $16 M of $16 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $250,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in California People named in the notice James Liu · Executive Officer, Director · Controller, Principal Accounting Officer and interim Principal Financial Officer Joshua Riggs · Executive Officer, Director · President and Chief Executive Officer and Director Alfred Kingsley · Director Andrew Arno · Director Andrew Last · Director Louis Silverman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Needham & Company, LLC (CRD 000016360) · New York, New York Sold in NY Signed by /s/ Joshua Riggs, President and Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Apr 25, 2024. Read the notice at the SEC .
equity, options SEC Apr 2021 $3 M Private placement after listing $2 to $10 million 75
OncoCyte Corp: Private sale, Apr 2021 × Investors in this round 75 investors had bought by the notice of Apr 29, 2021: 75 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $18 M offered; $14 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Douglas T Ross · Executive Officer Mitchell A Levine · Executive Officer Padmavathi T Sundar · Executive Officer Ronald A Andrews · Executive Officer, Director Alfred D Kingsley · Director Andrew J Last · Director Andy Levin Arno · Director Cavan T Redmond · Director Jennifer Levin Carter · Director Melinda Levin Griffith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Ronald Andrews, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 29, 2021. Read the notice at the SEC .
equity SEC Feb 2021 $5 M Private placement after listing $2 to $10 million 7
OncoCyte Corp: Private sale, Feb 2021 × Investors in this round 7 investors had bought by the notice of Mar 8, 2021: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Douglas T Ross · Executive Officer Mitchell A Levine · Executive Officer Padmavathi T Sundar · Executive Officer Ronald A Andrews · Executive Officer, Director Alfred D Kingsley · Director Andrew J Last · Director Andy Levin Arno · Director Cavan T Redmond · Director Jennifer Levin Carter · Director Melinda Levin Griffith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mitchell Levine, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 8, 2021. Read the notice at the SEC .
equity SEC Jan 2020 $5 M Private placement after listing $2 to $10 million 29
OncoCyte Corp: Private sale, Jan 2020 × Investors in this round 29 investors had bought by the notice of Feb 11, 2020: 29 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $11 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Albert Parker · Executive Officer Mitch Levine · Executive Officer Ronald Andrews · Executive Officer, Director Aditya Mohanty · Director Alfred Kingsley · Director Andrew Arno · Director Andrew Last · Director Cavan Redmond · Director Melinda Griffith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Contingent consideration of up to $6,000,000 additional shares may be issued to investors.”Signed by Mitch Levine, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 11, 2020. Read the notice at the SEC .
equity SEC Aug 2016 $11 M No. 3 $10 to $50 million 9
OncoCyte Corp: Raise no. 3, Aug 2016 × Investors in this round 9 investors had bought by the notice of Sep 9, 2016: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $511,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in California People named in the notice Russell Skibsted · Executive Officer William Annett · Executive Officer, Director Aditya Mohanty · Director Alfred Kingsley · Director Andrew Arno · Director Andrew Last · Director Cavan Redmond · Director Don Bailey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Cowen & Company, LLC (CRD 7616) · New York, New York Sold in CA, NY, PA Remarks in the notice On fees: “Cowen & Company paid $511,000 to act as placement agent for the Issuer.”On the amounts: “Total Amount Sold does not include Common Stock Warrants totaling 3,246,153 that were issued upon closing.”Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Sep 9, 2016. Read the notice at the SEC .
equity, options SEC Sep 2015 $8 M No. 2 $2 to $10 million 1
OncoCyte Corp: Raise no. 2, Sep 2015 × Investors in this round 1 investor had bought by the notice of Oct 15, 2015: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $11 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $787,500 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in California People named in the notice Karen B. Chapman · Executive Officer Kristine C. Mechem · Executive Officer Robert W. Peabody · Executive Officer, Director William Annett · Executive Officer, Director Aditya D. Mohanty · Director Alfred D. Kingsley · Director Andrew W. Arno · Director Cavan D. Redmond · Director Michael D. West · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total offering = 7,370,609 shares / Sold so far = 5,421,714 shares”Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Oct 15, 2015. Read the notice at the SEC .
equity SEC May 2015 $3 M No. 1 $2 to $10 million 2
OncoCyte Corp: Raise no. 1, May 2015 × Investors in this round 2 investors had bought by the notice of May 14, 2015: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $1,000,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $285,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in California People named in the notice Joseph Wagner · Executive Officer, Director Robert W. Peabody · Executive Officer, Director Aditya D. Mohanty · Director Alfred D. Kingsley · Director Michael D. West · Director William D. Annett · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed May 14, 2015. Read the notice at the SEC .
equity SEC